RWM
RCKT icon

Rialto Wealth Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Rialto Wealth Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-76
Closed -$187 – 1772
2025
Q2 		$187 Sell
76
-15
-16% -$76 ﹤0.01% 1402
2025
Q1 		$607 Buy
+91
New +$899 ﹤0.01% 733

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Rialto Wealth Management's RCKT Position: Q3 2025 in Review

Rialto Wealth Management sold out of Rocket Pharmaceuticals (RCKT) in Q3 2025, closing a stake of 76 shares — an estimated $187 sold.

Rialto Wealth Management first reported a position in RCKT in Q1 2025 and held it in 2 quarters. The position peaked at $607 in Q1 2025. 173 funds tracked by Wall St. Rank hold RCKT as of Q3 2025.

  • Rialto Wealth Management reported no remaining Rocket Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Rialto Wealth Management sold 76 Rocket Pharmaceuticals shares in Q3 2025, an estimated $187.
  • Rialto Wealth Management first reported a position in Rocket Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Rialto Wealth Management's Rocket Pharmaceuticals position peaked at $607 in Q1 2025.
  • 173 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2025.

Based on Rialto Wealth Management's 13F filing for Q3 2025, filed 7 Nov 2025.